Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT for Amarin Corporation

Share:
Related AMRN
Benzinga's Top Initiations
Amarin Offers New Clinical, Pre-Clinical Data at ACC Meeting Related to Effect of EPA Therapy in Statin-Treated Patients

In a company note published earlier today, Jefferies & Company, Inc. reiterated its Buy rating for Amarin Corporation (NASDAQ: AMRN) and raised its price target from $24.00 to $26.00.

Jefferies & Company went on to say “Yesterday, the patent office (PTO) posted unexpected positive office actions on three key patent applications based on MARINE: the core ‘889 application and two continuation applications ‘408 and '145. We believe these actions should lead to near-term issuance of these patents, which could provide AMR101 protection through 2030. We remain bullish on near-term approval of AMR101.”

Amarin Corporation closed yesterday at $13.16.

Latest Ratings for AMRN

DateFirmActionFromTo
May 2016JefferiesInitiates Coverage onBuy
Mar 2015HC WainwrightUpgradesBuy
Feb 2015SunTrust Robinson HumphreyUpgradesNeutralBuy

View More Analyst Ratings for AMRN
View the Latest Analyst Ratings

Posted-In: Jefferies & Company Inc.Analyst Color Price Target Reiteration Analyst Ratings

 

Related Articles (AMRN)

View Comments and Join the Discussion!